Your browser doesn't support javascript.
loading
ßTrCP1 promotes SLC35F2 protein ubiquitination and inhibits cancer progression in HeLa cells.
Colaco, Jencia Carminha; Chandrasekaran, Arun Pandian; Karapurkar, Janardhan Keshav; Birappa, Girish; Rajkumar, Sripriya; Gowda, D A Ayush; Suresh, Bharathi; Lee, Junwon; Singh, Vijai; Hong, Seok-Ho; Kim, Kye-Seong; Ramakrishna, Suresh.
Affiliation
  • Colaco JC; Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
  • Chandrasekaran AP; Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
  • Karapurkar JK; Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
  • Birappa G; Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
  • Rajkumar S; Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
  • Gowda DAA; Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
  • Suresh B; Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
  • Lee J; Institute of Vision Research, Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Eonjuro 211, Gangnam-Gu, Seoul, 06273, South Korea.
  • Singh V; Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, 382715, Gujarat, India.
  • Hong SH; Department of Internal Medicine, School of Medicine, Kangwon National University, Chuncheon, South Korea. Electronic address: shhong@kangwon.ac.kr.
  • Kim KS; Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea; College of Medicine, Hanyang University, Seoul, 04763, South Korea. Electronic address: ks66kim@hanyang.ac.kr.
  • Ramakrishna S; Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea; College of Medicine, Hanyang University, Seoul, 04763, South Korea. Electronic address: suresh.ramakris@gmail.com.
Biochem Biophys Res Commun ; 682: 27-38, 2023 11 19.
Article de En | MEDLINE | ID: mdl-37801987
ABSTRACT
The solute carrier family 35 F2 (SLC35F2) belongs to membrane-bound carrier proteins that are associated with multiple cancers. The main factor that determines cancer progression is the expression level of SLC35F2. Thus, identifying the E3 ligase that controls SLC35F2 protein abundance in cancer cells is critical. Here, we identified ßTrCP1 interacting with and reducing the SLC35F2 protein level. ßTrCP1 signals SLC35F2 protein ubiquitination and reduces SLC35F2 protein half-life. The mRNA expression pattern between ßTrCP1 and SLC35F2 across a panel of cancer cell lines showed a negative correlation. Additionally, the depletion of ßTrCP1 accumulated SLC35F2 protein and promoted SLC35F2-mediated cell growth, migration, invasion, and colony formation ability in HeLa cells. Overall, we demonstrate that ßTrCP1 acts as a tumor suppressor by controlling SLC35F2 protein abundance in cancer cells. The depletion of ßTrCP1 promotes SLC35F2-mediated carcinogenesis. Thus, we envision that ßTrCP1 may be a potential target for cancer therapeutics.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Ubiquitin-protein ligases / Tumeurs Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Biochem Biophys Res Commun Année: 2023 Type de document: Article Pays d'affiliation: Corée du Sud

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Ubiquitin-protein ligases / Tumeurs Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Biochem Biophys Res Commun Année: 2023 Type de document: Article Pays d'affiliation: Corée du Sud